Association of serotonin transporter (SLC6A4) & receptor (5HTR1A, 5HTR2A) polymorphisms with response to treatment with escitalopram in patients with major depressive disorder : A preliminary study
Autor: | Rakesh K Chadda, Mamta Sood, Aniruddha Basu, Ritushree Kukreti, Harpreet Kaur |
---|---|
Rok vydání: | 2015 |
Předmět: |
Adult
Male medicine.medical_specialty Genotype rs6311 Rs6313 lcsh:Medicine Citalopram Pharmacology Polymorphism Single Nucleotide General Biochemistry Genetics and Molecular Biology serotonin transporter (SLC6A4) polymorphism Gene Frequency Internal medicine mental disorders medicine Humans Escitalopram Genetic Predisposition to Disease Receptor Serotonin 5-HT2A Genetic Association Studies rs6295 Serotonin transporter pharmacogenetics Serotonin Plasma Membrane Transport Proteins Depressive Disorder Major HTR2A) - serotonin transporter (SLC6A4) polymorphism biology business.industry Antidepressant response lcsh:R General Medicine Middle Aged medicine.disease Receptor Serotonin 5-HT1A biology.protein Major depressive disorder Antidepressant response - pharmacogenetics - serotonin receptor polymorphism (HTR1A Original Article Female serotonin receptor polymorphism (HTR1A HTR2A) business Pharmacogenetics medicine.drug |
Zdroj: | The Indian Journal of Medical Research Indian Journal of Medical Research, Vol 142, Iss 1, Pp 40-45 (2015) |
ISSN: | 0971-5916 |
Popis: | Background & objectives: Genetic factors have potential of predicting response to antidepressants in patients with major depressive disorder (MDD). In this study, an attempt was made to find an association between response to escitalopram in patients with MDD, and serotonin transporter (SLC6A4) and receptor (5HTR1A, 5HTR2A) polymorphisms. Methods: Fifty five patients diagnosed as suffering from MDD, were selected for the study. The patients were treated with escitalopram over a period of 6-8 wk. Severity of depression, response to treatment and side effects were assessed using standardised instruments. Genetic variations from HTR1A (rs6295), HTR2A (rs6311 and rs6313) and SLC6A4 (44 base-pair insertion/deletion at 5-HTTLPR) were genotyped. The genetic data of the responders and non-responders were compared to assess the role of genetic variants in therapeutic outcome. Results: Thirty six (65.5%) patients responded to treatment, and 19 (34.5%) had complete remission. No association was observed for genotype and allelic frequencies of single nucleotide polymorphisms (SNPs) among remitter/non-remitter and responder/non-responder groups, and six most common side-effects, except memory loss which was significantly associated with rs6311 ( p0 =0.03). Interpretation & conclusions: No significant association was found between the SNPs analysed and response to escitalopram in patients with MDD though a significant association was seen between the side effect of memory loss and rs6311. Studies with larger sample are required to find out genetic basis of antidepressant response in Indian patients. |
Databáze: | OpenAIRE |
Externí odkaz: |